Know Your Investor: Orbimed (February’ 25 Edition)

Shots:

The February edition highlights OrbiMed Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and biotech sectors
In 2024, OrbiMed expanded its portfolio by adding 49 companies, investing approximately $6.08B across five funding rounds, including private and debt financing
For the complete report, contact us at connect@pharmashots.com

Founded in 1989, OrbiMed Advisors is a global healthcare investment firm led by 21 partners. The firm finances a broad range of companies, from early-stage startups to large multinationals, across private equity, public equity, royalty, and credit funds. Headquartered in New York City, OrbiMed has a global presence with offices in London, San Francisco, Shanghai, Hong Kong, Mumbai, and Herzliya.

OrbiMed primarily targets the biotechnology and healthcare sectors, investing in companies with the potential to innovate from the ground up. Its extensive portfolio includes over 195 companies, featuring notable names such as AbCellera, Acelyrin, Actus Medical, and Adaptive Biotechnologies.

In 2024, OrbiMed participated in five funding rounds, including PIPE and Series A-D, along with three private equity and one debt financing round. This led to the addition of several companies, including Candid Therapeutics, Belenos Biosciences, Avenzo Therapeutics, and Enyo Pharma, to its growing portfolio. The largest investment of the year went to Mirador Therapeutics, which secured $400M in a Series A funding round.

OrbiMed strategically invests in biopharmaceutical companies at the discovery and development stages, MedTech and medical device firms, as well as healthcare IT and service providers. The firm’s therapeutic focus spans across Autoimmune, Oncology, Cardiovascular diseases, Dermatology, Endocrine/Metabolic disorders, Gastrointestinal diseases, Hematology, Hepatology, Infectious diseases, Inflammation, Musculoskeletal disorders, Neurology, Pulmonary diseases. In terms of technological focus, OrbiMed prioritizes investments in antibodies, biologics, RNA-based therapies, and vaccines.

In 2024:

Invested in 49 companies

40.8% of investments were through PIPE

32.6% were through Series A and Series B

Key Investments in 2024:

$400M Series A funding to Mirador Therapeutics

$370M Private funding to Candid Therapeutics

$280M PIPE funding to Cullinan Oncology

Quarterly Investments in 2024:

Q1: 17 investments worth $2.67B

Q2: 7 investments worth $0.87B

Q3: 10 investments worth $1.05B

Q4: 15 investments worth $1.48B

The table below depicts the top 5 out of the 49 investments made by Orbimed Advisors:

Note: (For the complete report, reach out to us at connect@pharmashots.com with the subject line "Orbimed" or for early access to complete data for future reports and analysis register here: https://forms.office.com/r/VwFu6aUm80)